|
| Ref. | Antigen | Epitopes | Functional properties |
| (aa sequence, restriction molecules) |
|
| CD8 epitopes | | | |
|
|
Cooper et al. [58] | E1 | 306–315 (CSIYPGHITG, Patr-0402); 366–375 (GNWAKVLVVL, Patr-0601/0602) | cytotoxic epitopes identified in recovered champanzees |
| E2 | 621–629 (TINYTIFKI, Patr-2001); 651–665 (RCDLEDRDRSELSPL, Patr-0601) |
| P7 | 781–791 (KWVPGAVYTFY, Patr-0601) |
| NS2 | 997–1008 (INGLPVSARRGR, Patr-0402) |
| NS3 | 1629–1637 (GAVQNEITL, Patr-1701) |
| NS5A | 2055–2065 (MWSGTFPINAY, Patr-0601) |
|
| Dazert et al. [57] | NS5B | 2841–2849 (ARMILMTHF, HLA-B27) | IFN- secreting and protective epitope |
|
| core | 41–49 (GPRLGVRAT, HLA-B7); 88–96 (NEGCGWMGW, HLA-B44); 111–119 (DPRRRSRNL, HLA-B7) | |
| E1 | 207–214 (CPNSSIVY, HLA-B35); 322–330 (MMMNWSPTT) | |
| E2 | 541–551 (NTRPPLGNWFG, HLA-B57); 610–619 (YRLWHYPCTI, HLA-Cw7) | |
| NS2 | 831–840 (LSPYYKRYIS, HLA-A25); 941–960 (LGALTGTYVYNHLTPLRDWA); 957–964 (RDWAHNGL, HLA-B37) | |
| Lauer et al. [61] | NS3 | 1070–1089 (ATCINGVCWTVYHGAGTRTI); 1073–1081 (CINGVCWTV, HLA-A2); 1175–1183 HAVGLFRAA, HLA-A68); 1359–1367 (HPNIEEVAL, HLA-B35); 1395–1403 (HSKKKCDEL, HLA-B8); 1406–1415 (KLVALGINAV, HLA-A2); 1435–1443 (ATDALMTGY, HLA-A1); 1610–1627 (CLIRLKPTLHGPTPLLYR) | IFN- secreting epitopes identified in recovered individuals |
| NS4 | 1695–1702 (IPDREVLY, HLA-B35); 1745–1754 (VIAPAVQTNW, HLA-A24); 1751–1770 (VFTGLTHIDAHFLSQTKQSG); 1758–1766 (ETFWAKHMW, HLA-A25); 1771–1790 (GIQYLAGLSTLPGNPAIASL); 1801–1809 (LTTSQTLLF; HLA-B57); 1966–1976 (SECCTPCSGSW, HLA-B37); 1987–1995 (VLDSFKTWL, HLA-A2) | |
| NS5 | 2162–2170 (EPEPDVAVL, HLA-B35); 2225–2233 (ELIEANLLW, HLA-A25); 2461–2480 (TSRSACQRQKKVTFDRLQVL); 2594–2602 (ALYDVVTKL, HLA-A2); 2629–2637 (KSKKTPMGF, HLA-B57); 2819–2828 (TARHTPVNSW, HLA-A25); 2912–2921 (LGVPPLRAWR, HLA-B57) | |
|
|
Wedemeyer et al. [60] | core | 35–44 (YLLPRRGPRL, HLA-A2); 132–140 (DLMGYIPLV, HLA-A2) | cytotoxic and IFN- secreting epitopes identified in chronic & recovered individuals |
| NS3 | 1073–1081 (CVNGVCWTV, HLA-A2); 1406–1415 (KLVALGINAV, HLA-A2) |
|
| Urbani et al. [62] | NS3 | 1073–1081 (CVNGVCWTV, HLA-A2); 1406–1415 (KLVALGINAV, HLA-A2) | Differential expression of CD127 on IFN- secreting cells |
|
| CD4 epitopes | | | |
|
|
Day et al. [67] | NS3 | 1248–1262 (GYKVLVLNPSVAATL, HLA-0401); 1579–1597 (SGENLPYLVAYQATVCARA, HLA-0401) | tetramer-positive T cells identified in recovered individuals |
| NS4 | 1770–1790 (SGIQYLAGLSTLPGNPAIASL, HLA-0401) |
|
| CD4 epitopes | | | |
|
| Lasarte et al. [68] | core | 99–112 (SPRGSRPSWGPTDP, HLA-DR); 146–159 (GAARALAHGVRVLE, HLA-DR) | Epitopes recognized by IL-2 secreting Th cells in IFN- treatment responders |
|
|
Schulze zur Wiesch et al. [66] | NS3 | 1209–1219 (VFTDNSSPPVV, HLA-0201); 1251–1260 (VLVLNPSVAA, HLA-0101/0401/1104 & 0101); 1542–1550 (YMNTPGLPV; HLA-0701); 1587–1598 (VAYQATVCARAQ; HLA-1001) |
Broad specificity to NS3/4/5 proteins identified by proliferation and IFN- secretion in recovered individuals |
| NS4 | 1775–1785 (LAGLSTLPGNP, HLA-0401/0404/0407/1104); 1913–1922 (VQWMNRLIAF, HLA-1104); 1915–1924 (WMNRLIAFAS, HLA-1001) |
| NS5 | 2273–2286 (EILRKSRRFAQALP, HLA-1104); 2423–2436 (SYSWTGALVTPCAA; HLA-0701); 2577–2588 (ARLIVFPDLGVR, HLA-0404/0407); 2944–2954 (YLFNWAVRTKL, HLA-1104) |
|
| Antibody epitopes | | | |
|
| Law et al. [72] | E2 | 396-424/436–447/523–540 (conformational epitope) | Conserved cross-genotype, neutralizing antibody epitope |
|
| Meunier et al. [70] | E1 | 313–327 (ITGHRMAWDMMMNWS) | Conserved cross-genotype, neutralizing antibody epitope |
|
| Perotti et al. [71] | E2 | 412–423/528–535 (conformational epitope) | Conserved cross-genotype, neutralizing antibody epitope |
|
|
Zhang et al. [43] | E2 | 412–426 (QLINTNGSWHINSTA) | Conserved cross-genotype, neutralizing antibody epitope
Unconserved interfering antibody epitope |
| E2 | 434–446 |
|
